Clinical Trials Arena on MSN12h
Immunovant will not seek approval for MG therapy, despite hitting endpoints
Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...
Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright
Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating ...
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...
The American Journal of Managed Care9h
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular ...